Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy

This study has been completed.
Sponsor:
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00765232
First received: September 30, 2008
Last updated: December 21, 2011
Last verified: December 2011
Results First Received: November 18, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Nephrectomy
Laparoscopic Donor Nephrectomy
Interventions: Drug: Ketorolac
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were recruited from October 2008 to November 2010.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Ketorolac 90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Placebo 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.

Participant Flow:   Overall Study
    Ketorolac   Placebo
STARTED   57   54 
COMPLETED   57   54 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Ketorolac 90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Placebo 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Total Total of all reporting groups

Baseline Measures
   Ketorolac   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 57   54   111 
Age 
[Units: Years]
Mean (Standard Deviation)
 43  (11)   43  (13)   43  (12) 
Gender 
[Units: Participants]
     
Female   23   33   56 
Male   34   21   55 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Pain 'Right Now'   [ Time Frame: 24 hours after the end of surgery ]

2.  Primary:   Morphine Equivalents of Concomitant Pain Medication   [ Time Frame: 24 hours after the end of surgery ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Mitchell R. Humphreys MD
Organization: Mayo Clinic
phone: 480-301-8000
e-mail: humphreys.mitchell@mayo.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Mitchell R. Humphreys, M.D., Mayo Clinic
ClinicalTrials.gov Identifier: NCT00765232     History of Changes
Other Study ID Numbers: 08-000747 LDN
Study First Received: September 30, 2008
Results First Received: November 18, 2011
Last Updated: December 21, 2011